Abstract
A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.
Keywords:
SARS-CoV-2; neutralizing antibodies; receptor-binding domain; vaccine.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Neutralizing / immunology*
-
Antibodies, Viral / immunology*
-
COVID-19 / immunology*
-
Cell Line
-
HEK293 Cells
-
Humans
-
Mice
-
Pandemics / prevention & control
-
Protein Binding / immunology*
-
Protein Domains / immunology*
-
Recombinant Proteins / immunology
-
SARS-CoV-2 / immunology*
-
Spike Glycoprotein, Coronavirus / immunology
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Recombinant Proteins
-
Spike Glycoprotein, Coronavirus
Grants and funding
This study was supported by the Ministry of Science and Technology (MOST-109-3114-Y-001-001 and MOST-109-2327-B-002-009), National Taiwan University and Academia Sinica, Taiwan.